atai Life Sciences / Beckley Psytech (ATAI) — atai Life Sciences and Beckley Psytech completed their strategic combination to create AtaiBeckley, following shareholder approval at a November 4 extraordinary general meeting where roughly 98% of votes cast favored the deal.
Shareholders also approved redomiciliation to Delaware. The merger consolidates BPL-003 (mebufotenin) and atai's broader pipeline under one company positioned as a leading psychedelic mental-health developer.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.